Use of 2,3,5-substituted thiophene compound for enhancement of radiotherapy
The present disclosure relates to a composition for enhancing radiotherapy, the composition containing a 2,3,5-substituted thiophene compound of Formula 1 or a pharmaceutically acceptable salt thereof. The composition may increase the sensitivity of cancer cells to radiation, and thus may be advantageously used to enhance the effect of radiotherapy. Also provided is a method for anticancer radiotherapy, the method including steps of: administering the composition for enhancing radiotherapy to a subject; and irradiating the subject with radiation. Further provided is a method for enhancing the effect of radiotherapy, the method including a step of administering the composition for enhancing radiotherapy to a subject.
1 . A method for enhancing anticancer radiotherapy, the method comprising steps of: administering to a subject in need thereof an effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof; and irradiating the subject with radiation at 3 Gy twice at 7-day intervals, wherein the compound is administrated in combination with the radiation;
2 . The method of claim 1 , wherein the step of administering is performed before irradiation, after irradiation, or simultaneously with irradiation.
3 . The method of claim 1 , wherein the pharmaceutically acceptable salt is hydrochloride salt.
4 . A method for enhancing the effect of radiotherapy, the method comprising a step of administering to a subject in need thereof an effective amount of a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, wherein the subject has cancer, and the cancer is colorectal cancer, head and neck cancer or breast cancer:
wherein the radiotherapy is irradiating the subject with radiation at 3 Gy twice at 7-day intervals, wherein the compound is administered in combination with the radiation.
5 . The method of claim 4 , wherein the pharmaceutically acceptable salt is hydrochloride salt.
6 . The method of claim 4 , wherein the compound or pharmaceutically acceptable salt thereof is administered before irradiation, after irradiation, or simultaneously with irradiation.